The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Assessing the impact of atezolizumab in NSCLC
Liza Villaruz, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, discusses the effects of approving atezolizumab, an anti-PD-L1 monoclonal antibody, in resected non-small cell lung cancer (NSCLC). Atezolizumab has increased the efficacy of surgical resection by improving patient outcomes receiving surgery, and in the IMpower010 trial (NCT02486718), patients with tumors expressing PD-L1 on more than 50% of tumor cells had the most benefit. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
